Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Ardelyx
|
| gptkbp:acquisitionYear |
2016
|
| gptkbp:focus |
development of drugs for neurological disorders
|
| gptkbp:foundedIn |
1999
|
| gptkbp:founder |
gptkb:Ronald_W._Barrett
|
| gptkbp:headquartersLocation |
gptkb:Santa_Clara,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
XenoPort
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:gabapentin_enacarbil
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
gptkb:XNPT
|
| gptkbp:bfsParent |
gptkb:Ernest_Mario
|
| gptkbp:bfsLayer |
6
|